Vir Biotechnology Inc.

12/07/2021 | Press release | Distributed by Public on 12/07/2021 02:57

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant